New Two-Pronged attack on deadly alcohol liver disease
NCT ID NCT07060638
Summary
This study is testing whether treating both severe alcohol-related liver disease and the underlying alcohol addiction at the same time leads to better health outcomes. It compares a new drug (F-652) against a standard steroid (prednisone) for the liver, and a structured addiction program against basic advice. The goal is to see if this combined approach helps people survive longer and avoid serious liver complications and relapse to drinking.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL-ASSOCIATED HEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
Contact
-
Indiana University
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55902, United States
Contact
-
University of Louisville
RECRUITINGLouisville, Kentucky, 40292, United States
Contact
-
University of Texas Southwestern Medical School
RECRUITINGDallas, Texas, 15260, United States
Contact
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23284, United States
Contact
Conditions
Explore the condition pages connected to this study.